Pradžia › Lėtinė mielomonocitinė leukemija › Texas
Lėtinė mielomonocitinė leukemija klinikiniai tyrimai Texas
18 tyrimai dėl Lėtinė mielomonocitinė leukemija ieško dalyvių vietose Texas.
Miestai Texas
Oficialus tyrimo tekstas (anglų kalba)
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-15 · NCT04996875Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
- M D Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-14 · NCT03683433A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
- MD Anderson Cancer Center, Houston
Renkami dalyviai2 fazėLaukiami sveiki savanoriai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-11 · NCT06566742Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- M D Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-09-04 · NCT03383575Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
- MD Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-18 · NCT07033598Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
- AIR Care, Dallas
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-12 · NCT07143669Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
- M D Anderson Cancer Center, Houston
Renkami dalyviai2/3 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 70 · Visoms lytims · Atnaujinta 2026-08-11 · NCT04708054Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
- M D Anderson Cancer Center, Houston
Renkami dalyviai1/2 fazė
Amžius nuo 12 iki 80 · Visoms lytims · Atnaujinta 2026-08-07 · NCT05092451Personalized NK Cell Therapy in CBT
- M D Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius nuo 15 iki 80 · Visoms lytims · Atnaujinta 2026-07-30 · NCT02727803Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
- The University of Texas M. D. Anderson Cancer Center, Houston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-15 · NCT07128381A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
- M D Anderson Cancer Center, Houston
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-20 · NCT04239157CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- M D Anderson Cancer Center, Houston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-05-20 · NCT03896269A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
Renkami dalyviai2/3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-30 · NCT04256317Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- M D Anderson Cancer Center, Houston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-16 · NCT04140487A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- MD Anderson, Houston
Renkami dalyviai2 fazė
Amžius nuo 18 iki 66 · Visoms lytims · Atnaujinta 2026-03-17 · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- MD Anderson Cancer Center, Houston
Renkami dalyviai1 fazė
Amžius 12 ir vyresni · Visoms lytims · Atnaujinta 2026-03-16 · NCT06994676A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- MD Anderson Cancer Center, Houston
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-09 · NCT06950034Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- MD Anderson Cancer Center, Huston
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-08-26 · NCT03850574Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.